Does low-dose or very-low-dose rivaroxaban reduce clinically significant bleeding compared to standard vitamin K antagonist therapy in participants with atrial fibrillation undergoing PCI with stent placement?
In patients with atrial fibrillation undergoing PCI, rivaroxaban-based antithrombotic regimens reduce clinically significant bleeding compared to standard vitamin K antagonist plus DAPT.
In participants with atrial fibrillation undergoing PCI with placement of stents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding than was standard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months. The three groups had similar efficacy rates, although the observed broad confidence intervals diminish the surety of any conclusions regarding efficacy. (Funded by Janssen Scientific Affairs and Bayer Pharmaceuticals; PIONEER AF-PCI ClinicalTrials.gov number, NCT01830543 .).
Gibson et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: